Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07309432) titled 'Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy' on Dec. 17, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Regeneron Pharmaceuticals
Condition:
Allergic Conjunctivitis
Intervention:
Drug: REGN5713
Drug: REGN5715
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: January 19, 2026
Target Sample Size: 350
To know more, visit https...